🔗 Share this article

Ex-government leader Rishi Sunak has reinforced his call for a focused testing initiative for prostate gland cancer.

In a recently conducted conversation, he declared being "certain of the urgency" of establishing such a system that would be economical, achievable and "save countless lives".

These remarks come as the UK National Screening Committee reconsiders its decision from the previous five-year period not to recommend routine screening.

Journalistic accounts propose the authority may maintain its present viewpoint.

Olympic Champion Adds Support to Movement

Olympic cycling champion Sir Hoy, who has late-stage prostate gland cancer, supports men under 50 to be tested.

He recommends lowering the eligibility age for obtaining a prostate-specific antigen blood screening.

Currently, it is not automatically provided to men without symptoms who are younger than fifty.

The prostate-specific antigen screening remains disputed however. Measurements can increase for factors other than cancer, such as infections, leading to false positives.

Critics argue this can lead to unnecessary treatment and adverse effects.

Focused Screening Proposal

The suggested examination system would focus on males between 45 and 69 with a hereditary background of prostate cancer and men of African descent, who face twice the likelihood.

This demographic encompasses around over a million males in the Britain.

Organization calculations suggest the system would require £25m per year - or about £18 per participant - comparable to colorectal and mammary cancer testing.

The estimate includes twenty percent of eligible men would be notified each year, with a 72% response rate.

Medical testing (scans and biopsies) would need to rise by almost a quarter, with only a modest expansion in healthcare personnel, based on the analysis.

Medical Professionals Reaction

Several healthcare professionals remain doubtful about the effectiveness of testing.

They assert there is still a risk that men will be intervened for the cancer when it is not absolutely required and will then have to live with adverse outcomes such as bladder issues and impotence.

One prominent urology professional stated that "The challenge is we can often identify disease that doesn't need to be managed and we end up causing harm...and my concern at the moment is that risk to reward equation needs adjustment."

Patient Experiences

Personal stories are also affecting the debate.

A particular example involves a man in his mid-sixties who, after asking for a PSA test, was identified with the disease at the age of 59 and was advised it had metastasized to his pelvic area.

He has since experienced chemical therapy, beam therapy and endocrine treatment but is not curable.

The patient advocates testing for those who are potentially vulnerable.

"That is essential to me because of my sons – they are approaching middle age – I want them screened as soon as possible. If I had been screened at 50 I am confident I might not be in the circumstances I am currently," he stated.

Future Steps

The Screening Advisory Body will have to assess the evidence and arguments.

While the recent study indicates the consequences for workforce and accessibility of a testing initiative would be achievable, some critics have argued that it would take imaging resources from patients being treated for other conditions.

The ongoing discussion emphasizes the complicated trade-off between prompt identification and potential overtreatment in prostate cancer care.